---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-018731"
form_type: "8-K"
ticker: "NEPH"
cik: "0001196298"
company_name: "NEPHROS INC"
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:15:54.392929+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nephros Q2 revenue $2.3M (+44% YoY); net loss improves 35%; acquires GenArraytion, HDF module filed to FDA

## Summary
- Net revenue $2.3M (+44% YoY); net loss improved 35% to $1.1M; adjusted EBITDA improved 46% to ($0.8M).
- Water filtration segment rev $2.2M (+40% YoY); gross margin 56%; management expects 55-60%.
- Acquired GenArraytion, Inc. in July 2021 to expand PCR testing and pathogen detection capabilities.
- Filed FDA 510(k) for second-generation HDF Assist Module; anticipates clearance later this year for limited commercial launch.
- Cash and equivalents of $8.3M as of June 30, 2021.

## SEC filing metadata
- accession: 0001493152-21-018731
- form_type: 8-K
- ticker: NEPH
- cik: 0001196298
- company_name: NEPHROS INC
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1196298/000149315221018731/0001493152-21-018731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1196298/000149315221018731/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-018731
- JSON: https://secwatch.observer/filing/0001493152-21-018731.json
- Plain text: https://secwatch.observer/filing/0001493152-21-018731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.